77 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
51 | 26480253 | [Anti-diabetics and chronic kidney disease]. | 2015 Sep-Oct | 1 |
52 | 26487791 | Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin. | 2015 Oct | 1 |
53 | 23668534 | Combination therapy of dipeptidyl peptidase-4 inhibitors and metformin in type 2 diabetes: rationale and evidence. | 2014 Feb | 1 |
54 | 24106875 | Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review. | 2014 Mar | 1 |
55 | 24233023 | Metformin enhances glucagon-like peptide 1 via cooperation between insulin and Wnt signaling. | 2014 Feb | 1 |
56 | 24918793 | Evidence-based practice use of incretin-based therapy in the natural history of diabetes. | 2014 May | 1 |
57 | 25089625 | Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies. | 2014 | 2 |
58 | 25172519 | Mechanism of increase in plasma intact GLP-1 by metformin in type 2 diabetes: stimulation of GLP-1 secretion or reduction in plasma DPP-4 activity? | 2014 Oct | 2 |
59 | 25568561 | Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia. | 2014 Oct | 1 |
60 | 22850868 | Metformin protects against lipoapoptosis and enhances GLP-1 secretion from GLP-1-producing cells. | 2013 Mar | 4 |
61 | 23831441 | Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes. | 2013 Sep | 1 |
62 | 23955995 | The beneficial effect of metformin on β-cell function in non-obese Chinese subjects with newly diagnosed type 2 diabetes. | 2013 Nov | 1 |
63 | 23971789 | Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in type 2 diabetes. | 2013 Dec | 1 |
64 | 24321717 | Effects of aerobic exercise with or without metformin on plasma incretins in type 2 diabetes. | 2013 Dec | 2 |
65 | 22432846 | GLP-1 agonists exenatide and liraglutide: a review about their safety and efficacy. | 2012 Aug | 1 |
66 | 22982676 | Molecular mechanisms of lipoapoptosis and metformin protection in GLP-1 secreting cells. | 2012 Oct 12 | 1 |
67 | 21205107 | Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin. | 2011 Mar | 1 |
68 | 21517658 | Liraglutide: a review of the first once-daily GLP-1 receptor agonist. | 2011 Mar | 1 |
69 | 21971158 | Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. | 2011 Dec | 5 |
70 | 20722676 | Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial. | 2010 Sep | 1 |
71 | 20868233 | Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells. | 2010 Dec | 1 |
72 | 19318378 | Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. | 2009 Jun | 1 |
73 | 19385979 | The scientific evidence: vildagliptin and the benefits of islet enhancement. | 2009 May | 2 |
74 | 19744424 | Practical applications of therapy with a glucagon-like peptide-1 receptor agonist. | 2009 Sep | 1 |
75 | 17342635 | [Exenatide--an incretin-mimetic agent for the treatment of type 2 diabetes mellitus]. | 2007 Mar 16 | 1 |
76 | 18217246 | Clinical management strategies for type 2 diabetes. | 2007 Dec | 1 |
77 | 16987706 | GLP-1 and type 2 diabetes: physiology and new clinical advances. | 2006 Dec | 1 |